No­var­tis to ad­vance malar­ia pro­gram in­to PhI­II in bid to fight drug re­sis­tance

No­var­tis is mov­ing an an­ti-malar­ia drug in­to a Phase III tri­al that it hopes could pro­vide a new weapon against drug-re­sis­tant strains of the in­fec­tion.

The com­pa­ny and its Swiss non-prof­it part­ner Med­i­cines for Malar­ia Ven­ture, or MMV, an­nounced Wednes­day that they are mov­ing for­ward with the treat­ment, which us­es the ex­per­i­men­tal drug ganaplacide com­bined with a new for­mu­la­tion of cur­rent an­ti-malar­ia drug lume­fantrine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.